Andes Biotechnologies   Report issue

For profit Phase 1
Founded: Santiago Chile (2008)

Organization Overview

First Clinical Trial
2015
NCT02508441
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Andes Biotechnologies

Active Ingredients

Drugs in Phase 1 Trials (1)

andes-1537 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 1)

Gallbladder Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1